Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis.

Chalmers, James D; Metersky, Mark L; Feliciano, Joseph; Fernandez, Carlos; Teper, Ariel; Maes, Andrea; Hassan, Mariam; Chatterjee, Anjan

Chalmers, James D; Metersky, Mark L; Feliciano, Joseph; Fernandez, Carlos; Teper, Ariel; Maes, Andrea; Hassan, Mariam; Chatterjee, Anjan.

Afiliação

Chalmers JD; Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
Metersky ML; University of Connecticut School of Medicine, Farmington, CT, USA.
Feliciano J; Insmed Incorporated, Bridgewater, NJ, USA.
Fernandez C; Insmed Incorporated, Bridgewater, NJ, USA.
Teper A; Insmed Incorporated, Bridgewater, NJ, USA.
Maes A; Insmed Incorporated, Bridgewater, NJ, USA.
Hassan M; Insmed Incorporated, Bridgewater, NJ, USA.
Chatterjee A; Insmed Incorporated, Bridgewater, NJ, USA.

ERJ Open Res ; 9(3)2023 Jul.

Article em En | MEDLINE | ID: mdl-37143828

ABSTRACT

ABSTRACT

Brensocatib is a novel anti-inflammatory therapy in development for bronchiectasis treatment. Phase 2 WILLOW trial data demonstrate a low number needed to treat and negative number needed to harm, suggesting a favourable benefit-risk profile. https//bit.ly/3SbisW3.

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google